Digoxin Short Term Treatment Assessment Randomized Trial in AHF

University of Monastir500 enrolled

Overview

AHFS management is challenging and most of the used drugs has failed to decrease post-discharge mortality and readmission rates which represent the most important goal in AHFS. Digoxin processes many characteristics of a beneficial drug for heart failure, however recent publications has rose concerns about its safety profile and therefore decreasing its use. Whether digoxin is efficient and safe in short term treatment of acute heart failure is a question that should be studied.

AHFS management is challenging given the heterogeniety of the patient population, absence of a universally accepted definition, incomplete understanding of its pathophysiology, and lack of evidence based guidelines. The majority of patients appear to respond well to initial therapies consisting of loop diuretics and vasoactive agents. however, this treatments failed to decrease post-discharge mortality and readmission rates which represent the most important goal in AHFS. In the last few years, many drugs has been tested in AHFS setting trying to adress this issue, however results has been disappointing in term of efficacy and / or safety. Although evidence supports the beneficial effects of digoxin on hemodynamic, neurohormonal, and electrophysiological parameters in patients with CHF, recent publications has rose concerns about its safety profile and therefore decreasing its use. The effects of digoxin alone or in combination with other vasodilators are seen within few hours of its administration and result in increased cardiac output, decreased pulmonary wedge pressure, increased ejection fraction, and improved neurohormonal profile without changes in blood pressure. All this findings made us rose the question of whether digoxin is effective or not in short term treatment of acute heart failure ? Additionnel treatments for AHF were given according left to ACCF/AHA for the managementof heart failure . Blood testing for scanner digoxin magerments will be confirmed at H8, h24 and H72 after the post protocol treatment admession treatment administration.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

DOUBLE

Enrollment

500

Conditions

Acute Heart Failure

Interventions

DigoxinDRUG

Digoxin 0.25 mg pills

PlaceboDRUG

Placebo pills

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Able to provide informed written consent. * Male or female aged ≥18 years old. * Admitted for acute heart failure defined by the presence of dypnea at rest or with minimal exertion , pulmonary congestion on chest radiograph ; and increased natriutic peptide concentrations ( BNP \>=350 pg/ml) or NTproBNP \>=1400 pg/ml ) . * Able to be randomized within 12 hours from presentation to the hospital. Exclusion Criteria: * Pregnant or breast feeding women. * Known severe or terminal renal failure. * Previous hepatic impairment. * Major surgery within 30 days. * Hematocrit \< 25%. * Alteration of consciousness GCS \< 15 * Critically ill patients needing immediate mechanical hemodynamic of ventilatory support. * Confirmed or suspected diagnosis of ACS within 45 days before inclusion. * Severe arrhythmias including significant sinoatrial or atrioventricular blocks or WPW syndrome. * Implantable cardiac devices including pacemakers and defibrillators. * Hypertrophic obstructive, restrictive, or constrictive cardiomyopathy. * Noncardiac pulmonary edema, including suspected sepsis. * Severe pulmonary disease * Significant stenotic valvular disease . * Hyperkalemia \> 5.5 mmol /L . * Administration of an investigational drug or implantation of an investigational device or participation in another trial within 30 days before screening. * Previous treatment with digoxin within 15 days before inclusion or contra-indications to digoxin. * Inability to follow instructions or comply with follow-up procedures.

Locations (2)

Sahloul University Hospital

Hammam Sousse, Sousse Governorate, Tunisia

RECRUITING

Fattouma Bourguiba University Hospital

Monastir, Tunisia

RECRUITING

Outcomes

Primary Outcomes

30 days mortality and rehospitalization rate

Time frame: 30 days

Secondary Outcomes

Hemodynamic improvement

Change in hemodynamic parameters as quantified by the area under the curve of bio-impedance thoracic fluid contenant (TFC), lung ultrasound (LUS) congestion score and BNP serum levels, from baseline to day 3.

Time frame: 3 days

Need for hospitalization

Time frame: 3 days

Length of stay in hospital

Time frame: from baseline to hospital discharge

AUC of dyspnea VAS scores

Change in patient-reported dyspnea as quantified by the area under the curve (AUC) of visual analogue scale (VAS) scores (0-100 mm scale) : a dyspnea VAS score of 0 corresponds to the patient's subjective feeling of "I Can Breathe Normally" and a dyspnea VAS score of 100 corresponds to "I Can't Breathe At All.

Time frame: 3 days

Improvement of patient-reported dyspnea

Improvement of patient-reported dyspnea relative to the start of study drug using a 5 point likert scale at 6, 12, and 24 hours, where a responder was a patient with better or markedly betted dyspnea at all three of those time points.

Time frame: [Time Frame: 6, 12, and 24 hours from start of the study medication]

Dyspnea resolution time

defined as the time between the start of study drug and the reduction of at least 50% of the dyspnea VAS score from baseline.

Time frame: 3 days

Digoxin related adverse events

Central Contacts

Nouira Semir, Professor

CONTACT

73106000 semir.nouira@rns.tn

Bzeouich Nasri, MD

CONTACT

52919170 medecinasri@gmail.com

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.